• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康老龄化中神经退行性变、潜在认知能力和身体活动的血浆标志物。

Plasma markers of neurodegeneration, latent cognitive abilities and physical activity in healthy aging.

机构信息

Swedish School of Sport and Health Sciences, Stockholm, Sweden.

Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.

出版信息

Sci Rep. 2024 Sep 17;14(1):21702. doi: 10.1038/s41598-024-72806-0.

DOI:10.1038/s41598-024-72806-0
PMID:39289522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11408627/
Abstract

Blood-based biomarkers of neurodegeneration demonstrate great promise for the diagnosis and prognosis of Alzheimer's disease. Ultra-sensitive plasma assays now allow for quantification of the lower concentrations in cognitively unimpaired older adults, making it possible to investigate whether these markers can provide insight also into the early neurodegenerative processes that affect cognitive function and whether the markers are influenced by modifiable risk factors. Adopting an exploratory approach in 93 healthy older adults (65-75 years), we used structural equation modelling to investigate cross-sectional associations between multiple latent cognitive abilities (working memory, episodic memory, spatial and verbal reasoning) and plasma amyloid beta (Aβ42/Aβ40 ratio), phosphorylated-tau 181 (ptau-181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL), as well as the influence of device-measured habitual physical activity on these associations. The results showed that NfL was negatively associated with working memory, and that NfL interacted with moderate-to-vigorous physical activity in its association with episodic memory. The study has thereby demonstrated the potential of neurodegenerative plasma markers for improving understanding of normative cognitive aging and encourages future research to test the hypothesis that high levels of NfL, indicative of white matter pathology, limit the beneficial effect of physical activity on episodic memory in healthy aging.

摘要

基于血液的神经退行性变生物标志物在阿尔茨海默病的诊断和预后方面具有巨大的潜力。超灵敏的血浆检测现在可以定量检测认知正常的老年人中较低浓度的标志物,这使得研究这些标志物是否可以深入了解影响认知功能的早期神经退行性过程,以及标志物是否受可改变的风险因素影响成为可能。在 93 名健康老年人(65-75 岁)中采用探索性方法,我们使用结构方程模型研究了多个潜在认知能力(工作记忆、情景记忆、空间和言语推理)与血浆淀粉样蛋白β(Aβ42/Aβ40 比值)、磷酸化 tau 181(ptau-181)、神经胶质纤维酸性蛋白(GFAP)和神经丝轻链(NfL)之间的横断面关联,以及设备测量的习惯性体力活动对这些关联的影响。结果表明,NfL 与工作记忆呈负相关,并且 NfL 与中度至剧烈体力活动的相互作用影响其与情景记忆的关联。该研究表明神经退行性血浆标志物有可能改善对正常认知衰老的理解,并鼓励未来的研究检验假设,即高水平的 NfL 表明白质病理学,限制了体力活动对健康衰老中情景记忆的有益作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/3ad37679fa98/41598_2024_72806_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/b2e8dea30eca/41598_2024_72806_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/930ebca56f89/41598_2024_72806_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/3ad37679fa98/41598_2024_72806_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/b2e8dea30eca/41598_2024_72806_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/930ebca56f89/41598_2024_72806_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23c/11408627/3ad37679fa98/41598_2024_72806_Fig3_HTML.jpg

相似文献

1
Plasma markers of neurodegeneration, latent cognitive abilities and physical activity in healthy aging.健康老龄化中神经退行性变、潜在认知能力和身体活动的血浆标志物。
Sci Rep. 2024 Sep 17;14(1):21702. doi: 10.1038/s41598-024-72806-0.
2
Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.血液中的阿尔茨海默病和神经退行性疾病生物标志物可预测脑萎缩和认知能力下降。
Alzheimers Res Ther. 2024 Apr 30;16(1):94. doi: 10.1186/s13195-024-01459-y.
3
Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.基于血浆生物标志物预测轻度认知障碍患者的纵向认知下降和阿尔茨海默病转化。
Cells. 2024 Jun 22;13(13):1085. doi: 10.3390/cells13131085.
4
Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.血浆淀粉样蛋白、P-tau、GFAP 和 NfL 与路易体痴呆患者脑脊液、临床和认知特征的关联。
Neurology. 2024 Jun 25;102(12):e209418. doi: 10.1212/WNL.0000000000209418. Epub 2024 Jun 3.
5
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.血浆神经丝轻链与阿尔茨海默病影像学生物标志物的阶段特异性关联。
Brain. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342.
6
Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.阿尔茨海默病及相关疾病的血浆生物标志物与认知和认知衰退的关联:基于人群的 MYHAT 研究。
Alzheimers Dement. 2024 Jun;20(6):4199-4211. doi: 10.1002/alz.13829. Epub 2024 May 16.
7
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.血浆神经丝轻链、胶质纤维酸性蛋白和磷酸化 tau181 作为神经精神症状和相关临床疾病进展的生物标志物。
Alzheimers Res Ther. 2024 Jul 25;16(1):165. doi: 10.1186/s13195-024-01526-4.
8
Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.血浆淀粉样蛋白-β、总tau 和神经丝轻链对早期阿尔茨海默病的识别价值。
ACS Chem Neurosci. 2019 Aug 21;10(8):3479-3485. doi: 10.1021/acschemneuro.9b00095. Epub 2019 Jun 13.
9
Plasma Biomarkers of Brain Injury and Their Association With Brain MRI and Cognition in Type 1 Diabetes.1 型糖尿病患者脑损伤的血浆生物标志物及其与脑 MRI 和认知的关系。
Diabetes Care. 2024 Sep 1;47(9):1530-1538. doi: 10.2337/dc24-0229.
10
Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.阿尔茨海默病血液生物标志物的变化及其与全因痴呆症发病的关系。
JAMA. 2024 Oct 15;332(15):1258-1269. doi: 10.1001/jama.2024.6619.

引用本文的文献

1
Physical activity and blood-based biomarkers of neurodegeneration in community dwelling Australians from ISLAND (Island Study Linking Ageing and Neurodegenerative Disease).来自ISLAND(衰老与神经退行性疾病关联岛屿研究)的澳大利亚社区居民的身体活动与基于血液的神经退行性变生物标志物
Alzheimers Dement (Amst). 2025 Aug 17;17(3):e70166. doi: 10.1002/dad2.70166. eCollection 2025 Jul-Sep.
2
The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer's Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression.胶质纤维酸性蛋白在阿尔茨海默病神经病理学中的作用及其作为早期诊断和病情进展血液生物标志物的潜力。
Mol Neurobiol. 2025 Jul 21. doi: 10.1007/s12035-025-05219-3.

本文引用的文献

1
Effect of physical activity on risk of Alzheimer's disease: A systematic review and meta-analysis of twenty-nine prospective cohort studies.体力活动对阿尔茨海默病风险的影响:二十九项前瞻性队列研究的系统评价和荟萃分析。
Ageing Res Rev. 2023 Dec;92:102127. doi: 10.1016/j.arr.2023.102127. Epub 2023 Nov 17.
2
Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.抗淀粉样蛋白-β单克隆抗体治疗早期阿尔茨海默病的疗效:系统评价和荟萃分析。
Neurol Sci. 2024 Jun;45(6):2461-2469. doi: 10.1007/s10072-023-07194-w. Epub 2023 Nov 17.
3
Objectively-measured movement behaviors, systemic low-grade inflammation, and plasma neurofilament light chain in older adults: a population-based study.
老年人客观测量的运动行为、全身性低度炎症与血浆神经丝轻链:一项基于人群的研究。
Immun Ageing. 2023 Jul 25;20(1):36. doi: 10.1186/s12979-023-00363-7.
4
Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice.阿尔茨海默病的血浆生物标志物:现有检测方法、最新进展及对临床实践的意义综述
J Alzheimers Dis Rep. 2023 May 3;7(1):355-380. doi: 10.3233/ADR-230029. eCollection 2023.
5
Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia.联合基于血液的生物标志物预测阿尔茨海默病痴呆风险。
Nat Aging. 2021 Jan;1(1):26-28. doi: 10.1038/s43587-020-00008-0.
6
An umbrella review of randomized control trials on the effects of physical exercise on cognition.一项关于体力活动对认知影响的随机对照试验的伞式综述。
Nat Hum Behav. 2023 Jun;7(6):928-941. doi: 10.1038/s41562-023-01554-4. Epub 2023 Mar 27.
7
Neurofilament light level correlates with brain atrophy, and cognitive and motor performance.神经丝轻链水平与脑萎缩、认知及运动表现相关。
Front Aging Neurosci. 2023 Jan 5;14:939155. doi: 10.3389/fnagi.2022.939155. eCollection 2022.
8
Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.阿尔茨海默病连续体中的血浆 Aβ42/40 比值、p-tau181、GFAP 和 NfL:AIBL 队列的横断面和纵向研究。
Alzheimers Dement. 2023 Apr;19(4):1117-1134. doi: 10.1002/alz.12724. Epub 2022 Jul 21.
9
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
10
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.阿尔茨海默病协会关于阿尔茨海默病血液生物标志物的合理使用建议。
Alzheimers Dement. 2022 Dec;18(12):2669-2686. doi: 10.1002/alz.12756. Epub 2022 Jul 31.